

San Antonio Breast Cancer Symposium

Henry B. Gonzalez Convention Centre

December 7-10, 2021

Abstracts¹

Tuesday, December 7, 2021

CCTG MA.32 – A Phase III Randomized Double-Blind Placebo-Controlled Adjuvant Trial of Metformin vs Placebo in Early Breast Cancer

Time: Tuesday, December 7, 2021; 10:00 AM CT

Type: Oral

Session: General Session 1, Hall 3; 8:00 – 10:45 AM CT

Abstract: *CCTG MA.32, a phase III randomized double-blind placebo-controlled adjuvant trial of metformin (MET) vs placebo (PLAC) in early breast cancer (BC): Results of the primary efficacy analysis (clinical trials.gov NCT01101438)*

Abstract #: GS1-08

Authors: Goodwin PJ, Chen BE, Gelmon KA, Whelan TJ, Ennis M, Lemieux J, Ligibel JA, Hershman DL, Mayer IA, Hobday TJ, Bliss JM, Rastogi P, Rabaglio-Poretti M, Mukherjee SD, Mackey RR, Abramson VG, Oja C, Wesolowski R, Thompson AM, Rea DW, Stos PM, Shepherd LE, Stambolic V, Parulekar WR

Page #: 2446

Link: <https://www.abstractsonline.com/pp8/#!/10462/presentation/2161>

Wednesday, December 8, 2021

CCTG MAC.15/SWOG S1007 – A Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy Plus or Minus Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx For Positive Node, Endocrine Responsive Breast Cancer.

Time: Wednesday, December 8, 2021; 10:15 AM CT

Type: Oral

Session: General Session 2, Hall 3; 8:30 – 11:15 AM CT

Abstract: *Distant-disease free interval in participants (pts) with 1-3 positive lymph nodes (LN), hormone receptor-positive (HR+) and her2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < or = 25 randomized to endocrine therapy (ET) +/- chemotherapy (CT): SWOG s1007 (RxPONDER)*

Abstract #: GS2-07

¹Online abstracts are available on the SABCS website beginning March 2022. They are also viewable by using this link <https://www.sabcs.org/> and clicking on "To view the 2021 SABCS abstracts, please click here ...". Page numbers are provided for easier reference.

Authors: Kalinsky KM, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LA, Chia SKL, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Martin M, Kelly CM, Ruiz-Borrego M, Gil-Gil M, Arce-Salinas CH, Brain EGC, Lee ES, Pierga J-Y, Bermejo B, Ramos-Vasquez M, Jung KH, Ferrero J-M, Schott A, Shak S, Sharma P, Lew D, Miao J, Tripathy D, Pusztai L, Hortobagyi G.

Page #: 22

Link: <https://www.abstractsonline.com/pp8/#!/10462/presentation/647>

Thursday, December 9, 2021

CCTG MA.9/SWOG S8814 – Phase III Comparison of Adjuvant Chemoendocrine Therapy with CAF and Concurrent or Delayed Tamoxifen to Tamoxifen Alone in Postmenopausal Patients with Involved Axillary Lymph Nodes and Positive Receptors

Time: Thursday, December 9, 2021; 7:00 – 8:30 AM CT

Type: Poster

Session: Poster Discussion

Abstract: *Evaluation of the predicted sensitivity to endocrine therapy (SET_{2,3} index) and the 21-gene Breast Recurrence Score_R assay in node-positive postmenopausal breast cancer: Results from an analysis in the SWOG S8814 trial*

Abstract #: PD9-06

Authors: Speers CW, Symmans WF, Barlow WE, Trevarton A, The S, Du L, Rae JM, Shak S, Baehner FL, Sharma P, Pusztai L, Hortobagyi GN, Hayes DF, Albain KS, Godwin A, Thompson A.

Page #: 2415

Link: <https://www.abstractsonline.com/pp8/#!/10462/presentation/576>

CCTG MAC.28/NRG BR007 – A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage 1, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score ≤ 18 Breast Cancer (DEBRA)

Time: Thursday, December 9, 2021; 7:00 – 8:30 AM CT

Type: Poster

Session: Poster Session 3

Abstract: *Evaluating de-escalation of breast radiation (DEBRA) following lumpectomy for breast conservative treatment of stage 1, hr+, HER2-, RS ≤ 18 breast cancer: NRG-BR007 a phase III trial*

Abstract #: P3-18-04

Authors: White J, Anderson SJ, Harris EER, Mamounas EP, Stover DG, Ganz PA, Jaggi R, Cecchini RS, Bergom C, Theberge V, El-Tamer M, Zellars RC, Shumway DA, Chen G-P, Julian TB, Wolmark N

Page #: 1361

Link: <https://www.abstractsonline.com/pp8/#!/10462/presentation/1253>

Friday, December 10, 2021

CCTG MA.38 – Randomized Phase II Study Comparing Two Different Schedules of Palbociclib plus Second Line Endocrine Therapy in Women with Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer

Time: Friday, December 10, 2021; 7:00 – 8:30 AM CT

Type: Poster
Session: Poster Session 5 (7:00 – 8:30 AM CT)
Abstract: *Elevated plasma IL-8 predicts for reduced outcomes in CCTG MA.38, a phase 2 randomized trial of palbociclib in ER+/HER2- metastatic breast cancer patients*
Abstract #: P5-13-10
Authors: Polimera HV, Bhatt D, Shepherd LE, Gelmon K, Joy AA, Parulekar WR, Joshi M, Ali SM, Leitzel K, Truica C, Vasekar M, Drabick JJ, Menon H, Shah N, Maddukuri A, Moku P, Halstead ES, McKeone D, Umstead TM, Chen BE, Lipton A
Page #: 1973
Link: <https://www.abstractsonline.com/pp8/#!/10462/presentation/1619>
